Increased p21-activated kinase-1 expression is associated with invasive potential in uveal melanoma

Melanoma Research

Volumn 16, Issue 4, 2006, Pages 285-296

  Pavey, Sandra ^a   Zuidervaart, Wieke ^b   Van Nieuwpoort, Frans ^b   Packer, Leisl ^a   Jager, Martine ^b   Gruis, Nelleke ^b   Hayward, Nicholas ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gene expression; Invasion; p21 activated kinase 1; Uveal melanoma

Indexed keywords

MATRIGEL; P21 ACTIVATED KINASE 1; P21 ACTIVATED KINASE 7; PROTEIN KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL TYPE; CLINICAL ARTICLE; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DOWN REGULATION; EVALUATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA CELL; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; RANK SUM TEST; REGULATORY MECHANISM; SAMPLE; UPREGULATION; UVEA MELANOMA; WILCOXON SIGNED RANKS TEST; WOUND CLOSURE;

CELL MOVEMENT; COLLAGEN; DNA, NEOPLASM; DRUG COMBINATIONS; GENE EXPRESSION PROFILING; HUMANS; LAMININ; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 33746260317     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000222589.30117.f2     Document Type: Article

References (79)

1. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110:245-250.
2. Gamel JW, McLean IW, McCurdy JB. Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma. Cancer 1993; 71:2299-2305.
3. Hart IR, Saini A. Biology of tumour metastasis. Lancet 1992; 339: 1453-1457.
4. Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61:6322-6327.
5. Elshaw SR, Sisley K, Cross N, Murray AK, MacNeil SM, Wagner M, et al. A comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of alpha1beta1, alpha4beta1 and alpha6beta1 integrins. Br J Ophthalmol 2001; 85:732-738.
6. Woodward JK, Rennie IG, Elshaw SR, Burn JL, Sisley K. Invasive and noninvasive uveal melanomas have different adhesive properties. Eye 2005; 19:342-348.
7. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406:536-540.
8. Zuidervaart W, van der Velden PA, Hurks MH, van Nieuwpoort FA, Out-Luiting CJ, Singh AD, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer 2003; 89:1914-1919.
9. Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003; 63:2578-2584.
10. Ehlers JP, Worley L, Onken MD, Harbour JW. DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res 2005; 11:3609-3613.
11. Ehlers JP, Harbour JW. NBS1 expression as a prognostic marker in uveal melanoma. Clin Cancer Res 2005; 11:1849-1853.
12. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004; 64:7205-7209.
13. Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol 2005; 140:748-749.
14. van derVelden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, Krijgsman E, et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development. Int J Cancer 2003; 106:472-479.
15. Seftor EA, Meltzer PS, Kirschmann DA, Pe'er J, Maniotis AJ, Trent JM, et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 2002; 19:233-246.
16. Daniels RH, Hall PS, Bokoch GM. Membrane targeting of p21-activated kinase 1 (PAK1) induces neurite outgrowth from PC12 cells. EMBO J 1998; 17:754-764.
17. Manser E, Huang HY, Loo TH, Chen XQ, Dong JM, Leung T, Lim L. Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. Mol Cell Biol 1997; 17:1129-1143.
18. Sells MA, Boyd JT, Chernoff J. p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol 1999; 145:837-849.
19. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 2000; 275:36238-36244.
20. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998; 273:28238-28246.
21. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R. Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 2000; 275: 12041-12050.
22. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, et al. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004; 10:3448-3456.
23. Hu DN, McCormick SA, Ritch R, Pelton-Henrion K. Studies of human uveal melanocytes in vitro: isolation, purification and cultivation of human uveal melanocytes. Invest Ophthalmol Vis Sci 1993; 34:2210-2219.
24. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987; 38:137-147.
25. Cha D, O'Brien P, O'Toole EA, Woodley DT, Hudson LG. Enhanced modulation of keratinocyte motility by transforming growth factor-alpha (TGF-alpha) relative to epidermal growth factor (EGF). J Invest Dermatol 1996; 106:590-597.
26. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280:1614-1617.
27. Berens ME, Rief MD, Loo MA, Giese A. The role of extracellular matrix in human astrocytoma migration and proliferation studied in a microliter scale assay. Clin Exp Metastasis 1994; 12:405-415.
28. Giese A, Loo MA, Norman SA, Treasurywala S, Berens ME. Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins. J Cell Sci 1996; 109 (Pt 8):2161-2168.
29. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004; 23:4060-4067.
30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
31. Boyer B, Tucker GC, Valles AM, Franke WW, Thiery JP. Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells. J Cell Biol 1989; 109:1495-1509.
32. Kassis J, Lauffenburger DA, Turner T, Wells A. Tumor invasion as dysregulated cell motility. Semin Cancer Biol 2001; 11:105-117.
33. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993; 4:219-229.
34. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999; 18:345-357.
35. Seftor RE, Seftor EA, Hendrix MJ. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev 1999; 18:359-375.
36. Baker JK, Elshaw SR, Mathewman GE, Nichols CE, Murray AK, Parsons MA, et al. Expression of integrins, degradative enzymes and their inhibitors in uveal melanoma: differences between in vitro and in vivo expression. Melanoma Res 2001; 11:265-273.
37. Anastassiou G, Schilling H, Djakovic S, Bornfeld N. Expression of VLA-2, VLA-3, and alpha(v) integrin receptors in uveal melanoma: association with microvascular architecture of the tumour and prognostic value. Br J Ophthalmol 2000; 84:899-902.
38. Anastassiou G, Schilling H, Stang A, Djakovic S, Heiligenhaus A, Bornfeld N. Expression of the cell adhesion molecules ICAM-1, VCAM-1 and NCAM in uveal melanoma: a clinicopathological study. Oncology 2000; 58:83-88.
39. Woodward JK, Rennie IG, Elshaw SR, Burn JL, Sisley K. Invasive and noninvasive uveal melanomas have different adhesive properties. Eye 2005; 19:342-348.
40. Leisner TM, Liu M, Jaffer ZM, Chernoff J, Parise LV. Essential role of CIB1 in regulating PAK1 activation and cell migration. J Cell Biol 2005; 170:465-476.
41. Papakonstanti EA, Stournaras C. Association of PI-3 kinase with PAK1 leads to actin phosphorylation and cytoskeletal reorganization. Mol Biol Cell 2002; 13:2946-2962.
42. Bagnato A, Rosano L, Spinella F, Di Castro V, Tecce R, Natali PG. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004; 64:1436-1443.
43. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995; 268:233-239.
44. Gilmore AP, Romer LH. Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell 1996; 7:1209-1224.
45. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 1995; 55:2752-2755.
46. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, et al. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005; 65:9851-9860.
47. Vadlamudi RK, Kumar R. P21-activated kinases in human cancer. Cancer Metastasis Rev 2003; 22:385-393.
48. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995; 270:29051-29054.
49. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70:389-399.
50. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002; 2:133-142.
51. Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S, Knaus UG. A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids. J Biol Chem 1998; 273:8137-8144.
52. Lian JP, Huang R, Robinson D, Badwey JA. Products of sphingolipid catabolism block activation of the p21-activated protein kinases in neutrophils. J Immunol 1998; 161:4375-4381.
53. Vadlamudi RK, Li F, Adam L, Nguyen D, Ohta Y, Stossel TP, Kumar R. Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol 2002; 4:681-690.
54. Bagrodia S, Taylor SJ, Jordon KA, Van Aelst L, Cerione RA. A novel regulator of p21-activated kinases. J Biol Chem 1998; 273:23633-23636.
55. Daniels RH, Zenke FT, Bokoch GM. alphaPix stimulates p21-activated kinase activity through exchange factor-dependent and -independent mechanisms. J Biol Chem 1999; 274:6047-6050.
56. Bagrodia S, Cerione RA. Pak to the future. Trends Cell Biol 1999; 9: 350-355.
57. Bokoch GM, Wang Y, Bohl BP, Sells MA, Quilliam LA, Knaus UG. Interaction of the Nck adapter protein with p21-activated kinase (PAK1). J Biol Chem 1996; 271:25746-25749.
58. Zhao ZS, Manser E, Lim L. Interaction between PAK and nck: a template for Nck targets and role of PAK autophosphorylation. Mol Cell Biol 2000; 20:3906-3917.
59. Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ, Kumar R. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem 2001; 276:29403-29409.
60. Rashid T, Banerjee M, Nikolic M. Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology. J Biol Chem 2001; 276:49043-49052.
61. Howe AK, Juliano RL. Regulation of anchorage-dependent signal transduction by protein kinase A and p21-activated kinase. Nat Cell Biol 2000; 2:593-600.
62. Frost JA, Steen H, Shapiro P, Lewis T, Ahn N, Shaw PE, Cobb MH. Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins. EMBO J 1997; 16:6426-6438.
63. King AJ, Sun H, Diaz B, Barnard D, Miao W, Bagrodia S, Marshall MS. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 1998; 396:180-183.
64. Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB, et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation. J Cell Biol 2003; 162:281-291.
65. Eblen ST, Slack JK, Weber MJ, Catling AD. Rac-PAK signaling stimulates extracellular signal-regulated kinase (ERK) activation by regulating formation of MEK1-ERK complexes. Mol Cell Biol 2002; 22:6023-6033.
66. Zhou GL, Field J. Targeting PAK etk. Cancer Biol Ther 2004; 3:102-103.
67. Adams JC, Schwartz MA. Stimulation of fascin spikes by thrombospondin-1 is mediated by the GTPases Rac and Cdc42. J Cell Biol 2000; 150:807-822.
68. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987; 47:3239-3245.
69. Sieuwerts AM, Klijn JG, Foekens JA. Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane. Clin Exp Metastasis 1997; 15:53-62.
70. Woodward JK, Nichols CE, Rennie IG, Parsons MA, Murray AK, Sisley K. An in vitro assay to assess uveal melanoma invasion across endothelial and basement membrane barriers. Invest Ophthalmol Vis Sci 2002; 43:1708-1714.
71. Herlyn D, Iliopoulos D, Jensen PJ, Parmiter A, Baird J, Hotta H, et al. In vitro properties of human melanoma cells metastatic in nude mice. Cancer Res 1990; 50:2296-2302.
72. Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992; 10:111-120.
73. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T, et al. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 2003; 163:985-992.
74. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, et al. Detailed map of a region commonly amplified at 11q13→ q14 in human breast carcinoma. Cytogenet Cell Genet 1997; 79:125-131.
75. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003; 2:345-351.
76. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 2004; 10:658-667.
77. He H, Hirokawa Y, Manser E, Lim L, Levitzki A, Maruta H. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J 2001; 7:191-202.
78. He H, Hirokawa Y, Gazit A, Yamashita Y, Mano H, Kawakami Y, et al. The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation. Cancer Biol Ther 2004; 3:96-101.
79. Hirokawa Y, Tikoo A, Huynh J, Utermark T, Hanemann CO, Giovannini M, et al. Clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 2004; 10:20-26.